Presidio Property Trust, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Presidio Property Trust, Inc. (SQFT) on August 19, 2024. The filing discloses a change in the Company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and audit matters.
Material Changes
- Dismissal of Auditor: On August 19, 2024, the Audit Committee dismissed Baker Tilly US, LLP effective immediately.
- Engagement of New Auditor: On August 19, 2024, the Audit Committee engaged Moss Adams LLP to audit consolidated financial statements commencing for the year ending December 31, 2024.
- Audit Opinions: Reports by Baker Tilly for the years ended December 31, 2023, and 2022 did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, scope, or accounting principles.
- Disagreements: There were no disagreements with Baker Tilly on accounting principles, practices, or auditing scope during the relevant period.
Management Commentary, Risks, and Contingencies
The filing references material weaknesses in internal control over financial reporting previously disclosed in the 2023 Form 10-K. These weaknesses relate to a non-recurring significant transaction for income tax provision under ASC 740, specifically concerning:
- Lack of a formal review and approval process for the annual income tax provision related to REIT and non-REIT subsidiaries.
- Issues regarding the ownership of shares of Conduit Pharmaceuticals Inc. received in a de-SPAC transaction on September 22, 2023.
- Inadequate design of internal controls, including monitoring and entity-level controls, regarding the income tax provision.
The Audit Committee has authorized Baker Tilly to respond to inquiries from the new auditor regarding these material weaknesses. No consultations regarding accounting principles or disagreements occurred with Moss Adams prior to their engagement.
Investor Verification Checklist
- Verify the status of remediation efforts for the material weaknesses in internal controls over financial reporting related to income tax provisions.
- Review the letter from Baker Tilly US, LLP (Exhibit 16.1) to confirm their agreement with the statements regarding the dismissal and lack of disagreements.
- Monitor future filings for the transition of audit responsibilities to Moss Adams LLP and any impact on the 2024 audit timeline.
- Assess the ongoing implications of the Conduit Pharmaceuticals Inc. share ownership on the Company's tax provision and REIT status.